Avadel Pharmaceuticals plc (AVDL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
New Strong Sell Stocks for Nov. 5
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.
3 Biopharma Names I Am Buying After Avadel's Buyout
M&A activity has seen a notable pick-up in the biotech/biopharma industries over the past six weeks. This rise in deal volume has resulted in a nice rally in the sector, which has been a long-term laggard in a market driven by the AI narrative. In light of this improved investor enthusiasm, I have added to or established stakes in the three stocks highlighted in more detail in the paragraphs below.
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?
The mean of analysts' price targets for Avadel (AVDL) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know
The consensus price target hints at a 37.3% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Thomas S.
An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure
ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
